前言2025年4月24日,荃信生物宣布与CalderaTherapeutics达成超5.5亿美元授权合作,将其临床前长效双抗QX030N的全球权益“打包出售”。这是国产自免领域又一笔重磅交易——尚未进入临床的药物,为何能吸引LillyAsiaVentures等顶级风投押注?在双抗赛道内卷加剧的当下,荃信生物是“割肉求生”还是“借船出海”?QX030N:未进临床先获天价青睐,凭何实力?根据协议,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.